Cadence Capital Management’s bluebird bio BLUE Stock Holding History

Cadence Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-492	Closed	-$579K	–	663
2017 Q1	$579K	Buy	+492	New	+$502K	0.04%	482
2016 Q4	–	Sell	-814	Closed	-$715K	–	669
2016 Q3	$715K	Buy	+814	New	+$590K	0.05%	405
2015 Q2	–	Sell	-2,900	Closed	-$4.54M	–	616
2015 Q1	$4.54M	Sell	2,900 -1,855	-39%	-$2.45M	0.28%	100
2014 Q4	$5.65M	Buy	+4,755	New	+$3.18M	0.33%	80

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Cadence Capital Management's BLUE Position: Q2 2017 in Review

Cadence Capital Management sold out of bluebird bio (BLUE) in Q2 2017, closing a stake of 492 shares — an estimated $579K sold.

Cadence Capital Management first reported a position in BLUE in Q4 2014 and held it in 4 quarters. The position peaked at $5.65M in Q4 2014. 241 funds tracked by Wall St. Rank hold BLUE as of Q2 2017.

Cadence Capital Management reported no remaining bluebird bio position as of Q2 2017 after selling out during the quarter.
Cadence Capital Management sold 492 bluebird bio shares in Q2 2017, an estimated $579K.
Cadence Capital Management first reported a position in bluebird bio in Q4 2014 and held it in 4 quarters.
Cadence Capital Management's bluebird bio position peaked at $5.65M in Q4 2014.
241 funds tracked by Wall St. Rank held bluebird bio as of Q2 2017.

Based on Cadence Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.